Tag: $Abbvie Inc

US House committee opens investigation into Merck, AbbVie China drug trials

A bipartisan group of U.S. lawmakers has opened national security investigations into whether drugmakers Merck and AbbVie have been involved ​in clinical trials conducted in China that helped fuel the communist country’s military capability, according to letters seen by Reuters.

AbbVie bets $10.9 billion on Apogee in next-generation immunology growth push

 AbbVie said on Monday it would buy biotech Apogee Therapeutics for $10.9 billion, ​in its largest buyout in more than five years to strengthen its next-gen ‌immunology pipeline.

AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs

AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong ​demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-than-expected ‌decline in sales of its older medicine Humira.

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts

AbbVie (ABBV +3.15%) gave investors reason to cheer, reporting higher earnings than expected for a fifth straight quarter and raising its financial forecasts for the year.

AbbVie to buy drug developer Cerevel for $8.7 billion

Dec 6 (Reuters) – AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition.

AbbVie signs $10.1 bln deal to buy cancer drugmaker ImmunoGen

Nov 30 (Reuters) – AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, adding a promising drug for ovarian cancer to its portfolio of oncology treatments.

Roche’s cancer therapy gets US FDA nod, heating up competition with AbbVie

The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG’s experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from AbbVie Inc.